Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The study prematurely discontinued on July 27, 2009 due to poor recruitment and operational futility as a result of changes in clinical practice. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with gastrointestinal stromal tumors whose disease has progressed on imatinib 400 mg daily.
You may not be if
Current treatment with any chemotherapy other than imatinib.
Current treatment with any dose of imatinib other than 400 mg
